Press Releases of the Week
|
|
|
|
|
 XOCOVA® Becomes First Oral Option for Post-Exposure COVID-19 Prevention
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that the U.S. Food and Drug Administration (FDA) has approved XOCOVA®…
|
 EU Approves Expanded Label for Opdivo® + AVD in Advanced Hodgkin Lymphoma
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo® (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and…
|
 FoundationOne® Diagnostics Approved for TALZENNA®–XTANDI® Therapy
Foundation Medicine, Inc., a global, patient-focused precision medicine company, announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx and…
|
 BrainStorm Cell Therapeutics appoints Peter J. Pitts to its board.
BrainStorm Cell Therapeutics Inc. a leading developer of autologous stem cell therapies for neurodegenerative diseases, announced that Peter J. Pitts has been appointed to the Company's Board of…
|
 Nestlé and IdB Holding S.p.A. sign VOWST® licensing deal in Europe
Nestlé Health Science, a global leader in the science of nutrition, and IdB Holding S.p.A. (IdB), a global leader in the production of high potent active pharmaceutical ingredients for the…
|
 Ori Biotech and ImmuXell Announce Strategic Partnership and First Patient Dosed
Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, and ImmuXell Biotech, a Shanghai-based clinical-stage cell therapy company, announced their strategic partnership which…
|
 SK bioscience Signs Technology Transfer Agreement with Colombia’s VECOL to Advance Local Vaccine Manufacturing in Latin America
SK bioscience announced that it has signed an agreement with Colombia's state-owned pharmaceutical company VECOL for vaccine technology transfer and local manufacturing cooperation as part of…
|
 Presentations Highlight Results on LEROCHOL® (lerodalcibep-liga) Announced by LIB Therapeutics
LIB Therapeutics Inc. (LIB), a privately-held, biopharmaceutical company with a recently approved novel, monthly, small-dose, third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga…
|
 Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine
H. Lundbeck A/S (Lundbeck) announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing authorization for eptinezumab for use in adults with migraine.
|
 Hologic to Present New Data Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions
Hologic, Inc. and its subsidiary, Biotheranostics, Inc., announced new data demonstrating how the Breast Cancer Index® (BCI™) Test results influence extended endocrine therapy decisions for patients…
|
|
|
|
